Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

50.36 +1.21 (+2.47%)

Streaming Delayed Price Updated: 2:59 PM EST, Jan 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

44 45 Next >

European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment ↗

July 17, 2024

European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed.

Via Benzinga

3 Top Cancer Treatment Stocks to Buy Now ↗

July 17, 2024

These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term.

Via InvestorPlace

Positive News is Driving This Cancer Drug Maker’s Stock Higher

July 15, 2024

IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather

Via MarketBeat

The 3 Most Undervalued Pharma Stocks to Buy in July 2024 ↗

July 12, 2024

Pharma stocks can be great investments during times of growth and recession, and are made even better if the stock is undervalued.

Via InvestorPlace

Topics Economy

Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings ↗

July 29, 2024

The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.

Via Benzinga

Topics Economy

GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests ↗

July 26, 2024

New research suggests that GSK's Shingrix vaccine may reduce dementia risk, potentially revolutionizing treatment for older adults. The study, involving 200,000 people, indicates a significant...

Via Benzinga

Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial ↗

July 23, 2024

ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient...

Via Benzinga

3 Stocks Under $10 With the Potential for Massive Gains ↗

July 22, 2024

Discover the growth potential of top small-cap stocks in the consumer finance, healthcare equipment and pharmaceutical industries.

Via InvestorPlace

Top Research Reports For Apple, Lowe's & Shopify ↗

July 17, 2024

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Lowe's Companies, Inc., and Shopify Inc., as well as two micro-cap stocks MIND Technology, Inc., and...

Via Talk Markets

Is GSK a Top-Value Stock Right Now? ↗

July 17, 2024

GSK, a multinational pharma company, scans as a bargain.

Via The Motley Fool

GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season

July 11, 2024

From GSK plc

Via Business Wire

3 Dirt-Cheap Drug Developers With Blockbuster Potential ↗

July 11, 2024

These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent.

Via InvestorPlace

Health Officials Keep Close Eye On Bird Flu As It Infects Cows For The First Time ↗

July 10, 2024

Avian influenza continues to spread among animals and has infected four dairy workers in the US. Concerns about human-to-human transmission are low.

Via Benzinga

The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024 ↗

July 09, 2024

A full-throated bull market makes it tough to find undervalued stocks under $50, but these three could soon lead the charge higher.

Via InvestorPlace

Pfizer's RSV Vaccine Abrysvo Clears Concerns Over Preterm Birth Risk, Safety For Pregnant Women, New Study Shows ↗

July 08, 2024

Pfizer's RSV vaccine, Abrysvo, for pregnant women shows no increased risk of pre-term births, according to a study. Researchers found no significant difference in pre-term birth rates between...

Via Benzinga

United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win ↗

July 05, 2024

New leadership in the United Kingdom could make several sectors standout going forward. Here's what experts are saying after the election.

Via Benzinga

Topics ETFs

Upcoming Stock Spinoffs: Should You Pounce or Pass? ↗

July 04, 2024

Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in.

Via InvestorPlace

CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts ↗

July 03, 2024

CureVac layoffs are coming for 30% of the vaccine company's employees as it prepares for a restructuring that will save it over 30% in costs.

Via InvestorPlace

Topics Workforce

CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK ↗

July 03, 2024

CureVac stock is up on Wednesday as CVAC investors react to the company signing a new 1.4 billion euro licensing agreement with GSK.

Via InvestorPlace

GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B ↗

July 03, 2024

GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gains full control of vaccine candidates for influenza and COVID-19, while...

Via Benzinga

3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024 ↗

July 03, 2024

A modest amount of money can go a long way when it's put to work in highly innovative, game-changing businesses.

Via The Motley Fool

Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims ↗

July 02, 2024

A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to...

Via Benzinga

Topics Lawsuit

CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK ↗

June 27, 2024

The CDC's ACIP recommends RSV vaccines for adults 75+, and for those 60-74 with chronic conditions. GSK's Arexvy is approved for adults 50-59 at risk. A decision on adults 50-59 is pending further...

Via Benzinga

Why Is Moderna Stock Trading Lower On Wednesday? ↗

June 26, 2024

The CDC's Advisory Committee on Immunization Practices is set to discuss recommendations for RSV, influenza, and COVID-19 vaccines. Moderna's data shows vaccine efficacy drops to 50% after 18 months in...

Via Benzinga

Moderna Crumbles After RSV Vaccine Effectiveness Pales Vs. Pfizer, GSK Shots ↗

June 26, 2024

After 18 months, Moderna's RSV vaccine proved about 50% effective against lower respiratory tract disease.

Via Investor's Business Daily

Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC ↗

June 26, 2024

Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.

Via Benzinga

UK Chooses Pfizer Over GSK for Multi-Million Dose RSV Vaccine Contract ↗

June 24, 2024

Pfizer secures a UK contract to supply millions of doses of its Abrysvo RSV vaccine, surpassing GSK's bid. The agreement includes doses for older adults and pregnant mothers.

Via Benzinga

Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer ↗

June 20, 2024

GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency.

Via Benzinga

Topics Lawsuit

Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth

June 20, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth

June 20, 2024

From FN Media Group LLC

Via GlobeNewswire

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

44 45 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.